Why the study?
Does the AngQb vaccine reduce blood pressure in spontaneously hypertensive rats and safely induce immunogenicity in healthy volunteers?
Population
Spontaneously hypertensive rats (SHR) and 12 healthy human volunteers
Comparison
Angiotensin II-derived peptide conjugated to VLP… vs Virus-like particle alone; placebo; Ramipril 1…
Design
RCT, randomized, placebo-controlled
Authors
Loading...
Supports AngQb advancement to hypertensive patient trials; extends virus-like particle vaccination to hypertension research.
Does the AngQb vaccine reduce blood pressure in spontaneously hypertensive rats and safely induce immunogenicity in healthy volunteers?
A virus-like particle-based vaccine against angiotensin II effectively reduces blood pressure in hypertensive rats and is safe and immunogenic in healthy human volunteers, suggesting potential as a long-lasting antihypertensive therapy.
Ambühl et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: